These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9343807)

  • 21. On aggregating QALYs: a comment on Dolan.
    Johannesson M
    J Health Econ; 1999 Jun; 18(3):381-6. PubMed ID: 10537901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of therapeutic hypothermia after cardiac arrest.
    Merchant RM; Becker LB; Abella BS; Asch DA; Groeneveld PW
    Circ Cardiovasc Qual Outcomes; 2009 Sep; 2(5):421-8. PubMed ID: 20031872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using cost-effectiveness/cost-benefit analysis to allocate health resources: a level playing field for prevention?
    Phillips KA; Hotlgrave DR
    Am J Prev Med; 1997; 13(1):18-25. PubMed ID: 9037338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patients' views of explicit rationing: what are the implications for health service decision-making?
    Devlin N; Appleby J; Parkin D
    J Health Serv Res Policy; 2003 Jul; 8(3):183-6. PubMed ID: 12869346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis and health care resource allocation: decision rules under variable returns to scale.
    Elbasha EH; Messonnier ML
    Health Econ; 2004 Jan; 13(1):21-35. PubMed ID: 14724891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis in health care based on the capability approach.
    Gandjour A
    Gesundheitswesen; 2014 Oct; 76(10):e39-43. PubMed ID: 24165915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A note on cost-value analysis.
    Østerdal LP
    Health Econ; 2003 Mar; 12(3):247-50; discussion 251-3. PubMed ID: 12605468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Methods of comparative economic evaluations of therapies and for rational allocation of resources across sectors of health care systems - introduction, advantages, risks].
    Wasem J; Hessel F; Kerim-Sade C
    Psychiatr Prax; 2001 Jul; 28 Suppl 1():S12-20. PubMed ID: 11533902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gaussian process modeling in conjunction with individual patient simulation modeling: a case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis.
    Stevenson MD; Oakley J; Chilcott JB
    Med Decis Making; 2004; 24(1):89-100. PubMed ID: 15005958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing uncertainty in cost-effectiveness analyses: application to a complex decision model.
    Parmigiani G; Samsa GP; Ancukiewicz M; Lipscomb J; Hasselblad V; Matchar DB
    Med Decis Making; 1997; 17(4):390-401. PubMed ID: 9343797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Individual utilities are inconsistent with rationing choices: A partial explanation of why Oregon's cost-effectiveness list failed.
    Ubel PA; Loewenstein G; Scanlon D; Kamlet M
    Med Decis Making; 1996; 16(2):108-16. PubMed ID: 8778528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach.
    Elbasha EH
    Health Econ; 2005 May; 14(5):457-70. PubMed ID: 15386661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Theory and methods of economic evaluation of health care.
    Johannesson M
    Dev Health Econ Public Policy; 1996; 4():1-245. PubMed ID: 10158916
    [No Abstract]   [Full Text] [Related]  

  • 34. Cost-effectiveness of repeat medical procedures: kidney transplantation as an example.
    Hornberger JC; Best JH; Garrison LP
    Med Decis Making; 1997; 17(4):363-72. PubMed ID: 9343794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
    Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data.
    Briggs AH; Lozano-Ortega G; Spencer S; Bale G; Spencer MD; Burge PS
    Value Health; 2006; 9(4):227-35. PubMed ID: 16903992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty.
    Al MJ; Feenstra TL; Hout BA
    Health Econ; 2005 Jul; 14(7):655-67. PubMed ID: 15678518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a population-based cost-effectiveness model of chronic graft-versus-host disease in Spain.
    Crespo C; Pérez-Simón JA; Rodríguez JM; Sierra J; Brosa M
    Clin Ther; 2012 Aug; 34(8):1774-87. PubMed ID: 22835778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Power and sample size in cost-effectiveness analysis.
    Laska EM; Meisner M; Siegel C
    Med Decis Making; 1999; 19(3):339-43. PubMed ID: 10424840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimisation versus certainty: understanding the issue of heterogeneity in economic evaluation.
    Stevens W; Normand C
    Soc Sci Med; 2004 Jan; 58(2):315-20. PubMed ID: 14604617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.